SCHEMBL4896816

SCHEMBL4896816

CC(C)(C)c1cc(C(C)(C)C)c(O)c(S(=O)(=O)Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.42
CA1 P00915 2/20 0.42
HSP90AA1 P07900 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
TYR P14679 1/20 0.41
NR5A2 O00482 1/20 0.40
NR5A1 Q13285 1/20 0.40
GLRA3 O75311 1/20 0.40
GLRB P48167 1/20 0.40
CYP1A2 P05177 3/20 0.40
CYP2C9 P11712 3/20 0.40
CYP2C19 P33261 2/20 0.40
GABBR2 O75899 2/20 0.40
GABBR1 Q9UBS5 2/20 0.40
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6851698 0.83 CA2 (0.43) CA2CA1HSP90AA1SMN1; SMN2ALDH1A1
SCHEMBL6851693 0.83 CA2 (0.43) CA2CA1HSP90AA1SMN1; SMN2ALDH1A1
SCHEMBL4896805 0.81 SMN1; SMN2 (0.61) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL35141 0.77 CA2 (0.67) CA2CA1HSP90AA1SMN1; SMN2ALDH1A1
SCHEMBL4894218 0.75 CA2 (0.52) CA2CA1SMN1; SMN2ALDH1A1POLB
SCHEMBL29226791 0.74 CA2 (0.47) CA2CA1HSP90AA1SMN1; SMN2ALDH1A1
SCHEMBL8986512 0.73 CA2 (0.61) CA2CA1HSP90AA1SMN1; SMN2ALDH1A1
SCHEMBL29226894 0.73 HSP90AA1 (0.47) CA2CA1HSP90AA1SMN1; SMN2ALDH1A1
Ammonia Solution, Strong SCHEMBL29226877 0.73 CA2 (0.45) CA2CA1HSP90AA1SMN1; SMN2ALDH1A1
SCHEMBL4884903 0.73 CYP1A2 (0.38) CA2CA1SMN1; SMN2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US disclosed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP disclosed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255240-A1 Sulfonamide Derivatives FABP4, SQOR, CS CA2 1064/4885CA1 3874/4885HSP90AA1 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.